Nanomedicinal Strategies to Treat Multidrug-resistant Tumors: Current Progress

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2010 Jun 10

PMID 20528455

Citations 93

Authors

Xiaowei Dong

Russell J Mumper

Affiliations

Soon will be listed here.

Abstract

Multidrug resistance (MDR) is a major impediment to the success of cancer chemotherapy. P-glycoprotein is an important and the best-known membrane transporter involved in MDR. Several strategies have been used to address MDR, especially P-glycoprotein-mediated drug resistance in tumors. However, clinical success has been limited, largely due to issues regarding lack of efficacy and/or safety. Nanoparticles have shown the ability to target tumors based on their unique physical and biological properties. To date, nanoparticles have been investigated primarily to address P-glycoprotein and the observed improved anticancer efficacy suggests that nanomedicinal strategies provide a new opportunity to overcome MDR. This article focuses on nanotechnology-based formulations and current nanomedicine approaches to address MDR in tumors and discusses the proposed mechanisms of action.

Citing Articles

Tumor microenvironment-responsive nanoformulations for breast cancer.

Velapure P, Kansal D, Bobade C Discov Nano. 2024; 19(1):212.

PMID: 39708097 PMC: 11663212. DOI: 10.1186/s11671-024-04122-5.

Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders.

Kaur G, Arora J, Sodhi A, Bhatia S, Batra N Mol Biotechnol. 2024; .

PMID: 39446301 DOI: 10.1007/s12033-024-01301-8.

Investigation of therapeutic potential of the Il24-p20 fusion protein against breast cancer: an in-silico approach.

Qureshi S, Ahmed N, Rehman H, Amirzada M, Saleem F, Waheed K In Silico Pharmacol. 2024; 12(2):84.

PMID: 39301086 PMC: 11408464. DOI: 10.1007/s40203-024-00252-x.

Effect of Liposomal (Alb.) March Extract in the Treatment of Obesity Induced by High-Calorie Diet.

Patias N, de Queiroz E, Ferrarini S, Bomfim G, Aguiar D, Sinhorin A Biology (Basel). 2024; 13(7).

PMID: 39056728 PMC: 11274057. DOI: 10.3390/biology13070535.

Computational Frontiers in Aptamer-Based Nanomedicine for Precision Therapeutics: A Comprehensive Review.

Kumar S, Mohan A, Sharma N, Kumar A, Girdhar M, Malik T ACS Omega. 2024; 9(25):26838-26862.

PMID: 38947800 PMC: 11209897. DOI: 10.1021/acsomega.4c02466.

References

Alakhova D, Rapoport N, Batrakova E, timoshin A, Li S, Nicholls D . Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. J Control Release. 2009; 142(1):89-100. PMC: 3113470. DOI: 10.1016/j.jconrel.2009.09.026. View

Padera T, Stoll B, Tooredman J, Capen D, Tomaso E, Jain R . Pathology: cancer cells compress intratumour vessels. Nature. 2004; 427(6976):695. DOI: 10.1038/427695a. View

Ono C, Takao A, Atsumi R . Absorption, distribution, and excretion of DJ-927, a novel orally effective taxane, in mice, dogs, and monkeys. Biol Pharm Bull. 2004; 27(3):345-51. DOI: 10.1248/bpb.27.345. View

Rose W, Fairchild C, Lee F . Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol. 2001; 47(2):97-105. DOI: 10.1007/s002800000241. View

Padera T, Kadambi A, Tomaso E, Carreira C, Brown E, Boucher Y . Lymphatic metastasis in the absence of functional intratumor lymphatics. Science. 2002; 296(5574):1883-6. DOI: 10.1126/science.1071420. View

Patil Y, Swaminathan S, Sadhukha T, Ma L, Panyam J . The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials. 2009; 31(2):358-65. PMC: 2783414. DOI: 10.1016/j.biomaterials.2009.09.048. View

See Y, Carlsen S, Till J, Ling V . Increased drug permeability in Chinese hamster ovary cells in the presence of cyanide. Biochim Biophys Acta. 1974; 373(2):242-52. DOI: 10.1016/0005-2736(74)90148-5. View

Lv H, He Z, Liu X, Yuan J, Yu Y, Chen Z . Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs. J Cell Biochem. 2007; 102(1):75-81. DOI: 10.1002/jcb.21276. View

Mainardes R, Urban M, Cinto P, Khalil N, Chaud M, Evangelista R . Colloidal carriers for ophthalmic drug delivery. Curr Drug Targets. 2005; 6(3):363-71. DOI: 10.2174/1389450053765914. View

10.

Mechetner E, Roninson I . Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci U S A. 1992; 89(13):5824-8. PMC: 402110. DOI: 10.1073/pnas.89.13.5824. View

11.

Peer D, Karp J, Hong S, Farokhzad O, Margalit R, Langer R . Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2008; 2(12):751-60. DOI: 10.1038/nnano.2007.387. View

12.

Leonard G, Polgar O, Bates S . ABC transporters and inhibitors: new targets, new agents. Curr Opin Investig Drugs. 2002; 3(11):1652-9. View

13.

Alexis F, Rhee J, Richie J, Radovic-Moreno A, Langer R, Farokhzad O . New frontiers in nanotechnology for cancer treatment. Urol Oncol. 2008; 26(1):74-85. DOI: 10.1016/j.urolonc.2007.03.017. View

14.

Leu A, Berk D, Lymboussaki A, Alitalo K, Jain R . Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. 2000; 60(16):4324-7. View

15.

Batrakova E, Li S, Elmquist W, Miller D, Alakhov V, Kabanov A . Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br J Cancer. 2001; 85(12):1987-97. PMC: 2364003. DOI: 10.1054/bjoc.2001.2165. View

16.

SHUBIK P . Vascularization of tumors: a review. J Cancer Res Clin Oncol. 1982; 103(3):211-26. DOI: 10.1007/BF00409698. View

17.

Chavanpatil M, Patil Y, Panyam J . Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm. 2006; 320(1-2):150-6. DOI: 10.1016/j.ijpharm.2006.03.045. View

18.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

19.

Stege A, Kruhn A, Lage H . Overcoming multidrug resistance by RNA interference. Methods Mol Biol. 2009; 596:447-65. DOI: 10.1007/978-1-60761-416-6_20. View

20.

Stewart A, Canitrot Y, Baracchini E, Dean N, Deeley R, Cole S . Reduction of expression of the multidrug resistance protein (MRP) in human tumor cells by antisense phosphorothioate oligonucleotides. Biochem Pharmacol. 1996; 51(4):461-9. DOI: 10.1016/0006-2952(95)02220-1. View